PMID- 35254755
OWN - NLM
STAT- MEDLINE
DCOM- 20220309
LR  - 20220531
IS  - 1545-9616 (Print)
IS  - 1545-9616 (Linking)
VI  - 21
IP  - 3
DP  - 2022 Mar 1
TI  - Adjunctive Use of Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam in 
      Patients With Psoriasis Treated With Ixekizumab.
PG  - 235-240
LID - 10.36849/JDD.6396 [doi]
AB  - OBJECTIVE: To examine the effectiveness and safety of adjunctive treatment with 
      calcipotriene 0.005%/betamethasone dipropionate 0.064% (Cal/BD) foam in adult 
      patients with chronic plaque psoriasis who have localized residual plaques after 
      ≥24 weeks of treatment with ixekizumab biologic therapy. METHODS: This study 
      was a prospective, open-label, single-arm study of adult patients with 
      moderate-to-severe chronic plaque psoriasis who had suboptimal response after 
      ≥24 weeks of treatment with ixekizumab (residual 3–8% body surface area 
      [BSA] involvement). All patients continued treatment with ixekizumab and received 
      once-daily Cal/BD foam for 4 weeks, followed by every other day for weeks 8 to 
      12. The primary endpoint was treat-to-target BSA ≤1% at week 4. Additional 
      endpoints included the Physician’s Global Assessment (PGA) score, 
      PGA×BSA, and the patient-reported Dermatology Life Quality Index (DLQI). 
      Safety evaluations included assessments of adverse events (AEs) and local skin 
      reactions. RESULTS: Among 25 enrolled patients, 36% were female, and the mean age 
      was 50 years. After 4 weeks of daily Cal/BD foam, 56% of patients achieved the 
      treat-to-target goal of ≤1% BSA. Mean % BSA involvement, mean PGA score, and 
      composite PGA×BSA score decreased 4 weeks after the addition of Cal/BD 
      foam. Improvements in disease severity outcomes were maintained after reducing 
      Cal/BD dosing frequency. Cal/BD was generally safe and well-tolerated, with no 
      serious AEs reported. CONCLUSION: In real-world clinical practice, for patients 
      with moderate-to-severe plaque psoriasis who had residual plaques following 
      ≥24 weeks of ixekizumab monotherapy, adjunctive treatment with Cal/BD foam was 
      associated with notable and sustained improvements in disease control. J Drugs 
      Dermatol. 2022;21(3): 235-240. doi:10.36849/JDD.6396.
FAU - Bagel, Jerry
AU  - Bagel J
FAU - Nelson, Elise
AU  - Nelson E
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Drugs Dermatol
JT  - Journal of drugs in dermatology : JDD
JID - 101160020
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Dermatologic Agents)
RN  - 0 (Drug Combinations)
RN  - 143NQ3779B (calcipotriene)
RN  - 826Y60901U (betamethasone-17,21-dipropionate)
RN  - 9842X06Q6M (Betamethasone)
RN  - BTY153760O (ixekizumab)
RN  - FXC9231JVH (Calcitriol)
SB  - IM
MH  - Adult
MH  - Antibodies, Monoclonal, Humanized
MH  - Betamethasone/analogs & derivatives
MH  - Calcitriol/analogs & derivatives
MH  - *Dermatologic Agents/adverse effects
MH  - Drug Combinations
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Prospective Studies
MH  - *Psoriasis/drug therapy
MH  - Treatment Outcome
EDAT- 2022/03/08 06:00
MHDA- 2022/03/11 06:00
CRDT- 2022/03/07 14:31
PHST- 2022/03/07 14:31 [entrez]
PHST- 2022/03/08 06:00 [pubmed]
PHST- 2022/03/11 06:00 [medline]
AID - S1545961622P0235X [pii]
AID - 10.36849/JDD.6396 [doi]
PST - ppublish
SO  - J Drugs Dermatol. 2022 Mar 1;21(3):235-240. doi: 10.36849/JDD.6396.